Hellman Jordan Management Co. Inc. MA bought a new position in Allergan PLC. (NYSE:AGN) during the second quarter, Holdings Channel reports. The institutional investor bought 5,640 shares of the company’s stock, valued at approximately $1,371,000. Allergan PLC. comprises 2.9% of Hellman Jordan Management Co. Inc. MA’s holdings, making the stock its 4th largest position.

A number of other large investors also recently added to or reduced their stakes in AGN. GWM Advisors LLC increased its stake in Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after buying an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY increased its stake in Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after buying an additional 6 shares during the last quarter. Trust Co increased its stake in Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after buying an additional 10 shares during the last quarter. JNBA Financial Advisors increased its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. Finally, Tarbox Group Inc. increased its stake in Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock worth $572,000 after buying an additional 15 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.213% during mid-day trading on Tuesday, hitting $232.145. 594,744 shares of the stock traded hands. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company’s 50 day moving average is $245.54 and its 200 day moving average is $238.65. The firm has a market capitalization of $77.61 billion, a P/E ratio of 7.073 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.35 earnings per share. On average, equities analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/hellman-jordan-management-co-inc-ma-buys-new-stake-in-allergan-plc-agn/1490765.html.

A number of equities research analysts have issued reports on the stock. UBS AG reiterated a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Monday, May 15th. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a report on Monday, June 26th. Wells Fargo & Company restated an “outperform” rating and set a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Argus restated a “buy” rating and set a $280.00 price target on shares of Allergan PLC. in a report on Monday. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a report on Wednesday, May 10th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and an average price target of $275.49.

In related news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.